Document is current
Any future updates will be listed below
-
Authors
Kato, Taigo https://orcid.org/0000-0002-8681-1407
Shiota, Masaki https://orcid.org/0000-0002-3306-4858
Nishimoto, Koshiro
Matsubara, Nobuaki
Osawa, Takahiro
Abe, Takashige
Yasumizu, Yota https://orcid.org/0000-0002-1725-6454
Tanaka, Nobuyuki
Yamamoto, Yoshiyuki
Ishizuya, Yu
Abutani, Hikaru
Bando, Hideaki
Fujisawa, Takao
Nakamura, Yoshiaki https://orcid.org/0000-0002-5241-6855
Oya, Mototsugu
Shinohara, Nobuo
Eto, Masatoshi
Yoshino, Takayuki https://orcid.org/0000-0002-0489-4756
Nonomura, Norio https://orcid.org/0000-0002-6522-6233
- License Information
-
More Information
Article History
Received: 25 September 2024
Revised: 25 January 2025
Accepted: 12 March 2025
First Online: 5 May 2025
Competing interests
: TK reports honoraria from MSD. HB reports research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly in Japan. TF reports honoraria for lectures from Amelieff Co. Ltd.; YN reports an advisory role for Guardant Health Pte Ltd., Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation, Gilead Sciences, Inc.; speakers’ bureau from Guardant Health Pte Ltd., MSD K.K., Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Becton, Dickinson and Company, Guardant Health Japan Corp; research funding from Seagen, Inc., Genomedia Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc., Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. HA is an employee of Chugai Pharmaceutical Co., Ltd. TY reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical and MSD K.K; consulting fee from Sumitomo Corp.; and research grant from Amgen, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo. Eisai, FALCO biosystems, Genomedia, MEDICAL & BIOLOGICAL LABORATORIES, Merus N.V., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical. NN received honoraria from MSD, Merck Biopharma, Ono Pharmaceutical, and Bristol-Myers Squibb.
: This study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The SCRUM-Japan MONSTAR SCREEN study was approved by the Institutional Review Board of each participating institution and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol nos. UMIN000036749). All participants provided written informed consent.
